Mark Coleman's Insider Trades & SAST Disclosures
Mark Coleman's most recent trade in Axsome Therapeutics Inc was a trade of 9,127 Common Stock done at an average price of $9 . Disclosure was reported to the exchange on Jan. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Coleman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.00 per share. | 03 Jan 2025 | 9,127 | 57,137 (0%) | 0% | 9 | 82,143 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 9,127 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 19 Nov 2024 | 33,410 | 48,010 (0%) | 0% | 5.9 | 198,455 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2024 | 33,410 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 5,799 | 5,799 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 75.21 per share. | 28 May 2024 | 5,249 | 19,848 (0%) | 0% | 75.2 | 394,775 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 75.14 per share. | 28 May 2024 | 5,248 | 14,600 (0%) | 0% | 75.1 | 394,333 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 5,681 | 5,681 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 2,870 | 2,870 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 03 Jan 2023 | 17,501 | 25,097 (0%) | 0% | 1.3 | 22,751 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 17,501 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 16,976 | 16,976 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 15 Mar 2022 | 3,496 | 7,596 (0%) | 0% | 1.3 | 4,545 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 3,496 | 17,501 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 2,798 | 2,798 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 35.10 per share. | 18 Nov 2021 | 1,021 | 422,428 (1%) | 0% | 35.1 | 35,837 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 35.07 per share. | 18 Nov 2021 | 409 | 421,407 (1%) | 0% | 35.1 | 14,344 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,325 | 7,325 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 58.15 per share. | 12 May 2021 | 500 | 420,998 (1%) | 0% | 58.2 | 29,075 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 1,201 | 1,201 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Aug 2020 | 397,998 | 397,998 (1%) | 1% | 0 | Common Stock | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Aug 2020 | 397,998 | 5,700 (0%) | 1% | 0 | Common Stock | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 78.50 per share. | 29 Jun 2020 | 650 | 403,698 (1%) | 0% | 78.5 | 51,025 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges